Dalmelitinib is an orally active selective c-Met kinase inhibitor ( IC 50 : 2.9 nM) that binds to the ATP-binding region of c-Met.Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK . Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC).